BioCorRx (BICX) AI Stock Analysis

6 Followers

BioCorRx

(Other OTC:BICX)

Select Model

Rating:38Underperform

Price Target:$0.24▲(16.34% Upside)

Action:downgraded

Date:08/22/26

The overall score is severely depressed, driven primarily by the company's insolvent balance sheet and unprofitable, cash-burning operations. The technical trend is firmly bearish, and the negative P/E ratio confirms a lack of fundamental value. The company faces significant viability risks without a major turnaround or capital infusion.

Positive Factors

High Gross MarginA gross margin near 71% indicates that BioCorRx’s products and services can retain substantial value after direct costs. If revenue scales without equivalent cost growth, this underlying economics could support improved operating leverage and eventual profitability.

Negative Factors

Small, Declining RevenueVery small revenue and a 10.3% decline indicate that BioCorRx has not yet established a strong or consistently expanding operating base. Limited scale makes fixed costs harder to absorb and leaves results highly sensitive to changes in demand or program activity.

BioCorRx (BICX) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $5.98M
Dividend Yield: ―
Average Volume (3M): 3,618
Price to Earnings (P/E): -1.6
Beta (1Y): -0.04
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 3
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Care Facilities

BioCorRx Business Overview & Revenue Model

Company Description

BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings...

How the Company Makes Money

BioCorRx’s public disclosures historically describe revenue generation tied to (a) sales of recovery- and wellness-related products and (b) service-based offerings connected to addiction treatment and related programs delivered via company initiative...

BioCorRx Financial Statement Overview

Summary

Financial health is critically weak. The company is deeply unprofitable with a net loss of $3.16M against $0.79M in declining revenue. The balance sheet is insolvent with negative equity of -$12.47M, and operations are burning cash at -$2.36M. While cash burn has slightly improved, the capital structure is unsustainable.

Income Statement

12Very Negative

Balance Sheet

3Very Negative

Cash Flow

8Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Mar 2022
Income Statement
Total Revenue	786.62K	797.24K	7,665	89.16K	213.84K	48.27K
Gross Profit	480.39K	691.38K	5,998	53.17K	198.56K	42.39K
EBITDA	-3.33M	-2.60M	-3.59M	-2.68M	-3.15M	-4.48M
Net Income	-3.16M	-3.44M	-5.11M	-3.77M	-4.37M	-5.80M
Balance Sheet
Total Assets	1.91M	2.15M	385.94K	388.89K	766.59K	819.98K
Cash, Cash Equivalents and Short-Term Investments	21.24K	139.36K	88.03K	65.22K	68.61K	85.84K
Total Debt	7.66M	2.13M	7.11M	1.81M	1.68M	1.77M
Total Liabilities	14.38M	13.67M	12.74M	10.34M	8.97M	7.78M
Stockholders Equity	-12.22M	-11.22M	-12.12M	-9.82M	-8.08M	-6.84M
Cash Flow
Free Cash Flow	-2.36M	-2.30M	-1.10M	-1.85M	-2.04M	-3.59M
Operating Cash Flow	-2.36M	-2.30M	-1.10M	-1.85M	-2.04M	-3.54M
Investing Cash Flow	0	0	0	0	0	-50.00K
Financing Cash Flow	2.26M	2.35M	1.12M	1.85M	2.02M	3.08M

BioCorRx Technical Analysis

Technical Analysis SentimentNegative

Last Price0.20

Price Trends

50DMA0.22Negative

100DMA0.25Negative

200DMA0.31Negative

Market Momentum

MACD-0.01Positive

RSI43.12Neutral

STOCH-3.11Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BICX, the sentiment is Negative. The current price of 0.20 is below the 20-day moving average (MA) of 0.22, below the 50-day MA of 0.22, and below the 200-day MA of 0.31, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.12 is Neutral, neither overbought nor oversold. The STOCH value of -3.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BICX.

BioCorRx Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

BICX against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AIDX	43Neutral	$2.61M	-0.29	-387.27%	―	―	―
MNDR	43Neutral	$1.14M	-0.04	-27.32%	―	4.47%	92.03%
XWEL	43Neutral	$5.71M	-0.10	317.52%	―	-7.58%	-30.33%
BICX	38Underperform	$5.98M	-1.58	26.14%	―	―	―

* Healthcare Sector Average

Performance Comparison

BICX and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
BICX	BioCorRx	0.20	-0.25	-54.91%
XWEL	Xwell, Inc.	0.56	-0.27	-32.65%
NIVF	Newgenivf Group Limited	0.28	-6538.48	-100.00%
MNDR	Mobile-health Network Solutions Class A	0.93	-10.05	-91.52%
BMGL	Basel Medical Group Ltd	0.57	-13.95	-96.07%
AIDX	20/20 Biolabs, Inc.	0.20	-23.65	-99.15%

BioCorRx Corporate Events

Executive/Board Changes

BioCorRx Announces Board Resignation of Director DeVarney

Neutral

Sep 4, 2026

On August 31, 2026, BioCorRx Inc. announced that Kate Beebe DeVarney, Ph.D., resigned from her role as a member of the company’s board of directors, effective the same day. The company stated that her resignation was not due to any disagreement with...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 22, 2026

BioCorRx AI Stock Analysis